|
Variable
|
Forward stepwise
|
Backward stepwise
|
|---|
| |
HRa(95% CIb)
|
p
|
HR (95% CI)
|
p
|
|---|
|
Location of tumor
| |
0.085
| |
0.001*
|
|
Head
|
-
| |
1
| |
|
Body and tail
|
-
| |
2.452 (1.414-4.253)
| |
|
Differentiation
| |
0.001*
| |
<0.001*
|
|
Well
|
1
| |
1
| |
|
Moderate
|
2.368 (1.120-5.007)
|
0.024*
|
2.163 (0.994-4.706)
|
0.052
|
|
Poor
|
6.603 (2.515-17.338)
|
<0.001*
|
7.076 (2.655-18.857)
|
<0.001*
|
|
TNM staging
| |
0.175
| |
0.014*
|
|
IA + IB
|
-
| |
1
| |
|
IIA
|
-
|
0.929
|
3.395 (1.414-8.148)
|
0.006*
|
|
IIB
|
-
|
0.922
|
3.551 (1.523-8.277)
|
0.003*
|
|
III + IV
|
-
|
0.077
|
4.218 (1.652-10.768)
|
0.003*
|
|
Serum CA19-9 (kU/L)
| |
0.021*
| |
0.008*
|
|
≤ 39
|
1
| |
1
| |
|
> 39
|
1.914 (1.105-3.318)
| |
2.817 (1.313-6.043)
| |
|
Serum CA50 (kU/L)
| |
0.535
| |
0.085
|
|
≤ 25
|
-
| |
1
| |
|
> 25
|
-
| |
0.552 (0.280-1.086)
| |
|
Serum CEA (μg/L)
| |
0.265
| |
0.089
|
|
≤ 4.3
|
-
| |
1
| |
|
> 4.3
|
-
| |
1.554 (0.934-2.584)
| |
|
MUC4 (2-ΔCt)
| |
0.001*
| |
0.010*
|
|
Low (<0.056)
|
1
| |
1
| |
|
High (≥0.056)
|
2.281 (1.415-3.677)
| |
1.976 (1.174-3.326)
| |
|
MUC4/Y (2-ΔCt)
| |
0.067
| |
0.243
|
|
Low (<0.0044)
|
-
| |
-
| |
|
High (≥0.0044)
|
-
| |
-
| |
-
aHR, hazard ratio; bCI, confidence interval; *
p <0.05.
